Education&ScienceEducational Article

Dyspnoea relief as an inherent benefit of high flow nasal cannula therapy: A laboratory randomized trial in healthy humans 

January 2024

Author:Clara Bianquis, Camille Rolland-Debord, Isabelle Rivals, Thomas Similowski, Capucine Morélot-Panzini

Comment by Mark Lavercombe: The researchers in this fascinating study induced dyspnoea using thoracoabdominal loading in 32 healthy adults without respiratory disease and with normal body mass index. High-flow nasal cannulae were used to administer either FiO2 21% or 100%. Visual analogue ratings of dyspnoea were completed, and showed both high-flow therapies were associated with reduction in symptoms, with no difference between FiO2 21% or 100%. There were also reductions in patient reported chest tightness and work/effort sensations. The authors hypothesise that the mechanism was reduction in afferent-reafferent mismatch. Further studies in patients with respiratory disease are recommended.